https://news.medxy.ai/ja/%e5%bf%83%e4%b8%8d%e5%85%a8%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e9%80%a3%e7%b6%9a%e3%83%a2%e3%83%8b%e3%82%bf%e3%83%aa%e3%83%b3%e3%82%b0%e4%b8%8b%e3%81%ae%e4%b8%8d%e6%95%b4%e8%84%88%e8%b2%a0%e8%8d%b7/Medxy AIja2026-06-03T09:39:35-07:00心不全における連続モニタリング下の不整脈負荷と臨床反応：ALLEVIATE-HF試験からの所見 https://news.medxy.ai/vi/ganh-nang-loan-nhip-va-dap-ung-lam-sang-khi-theo-doi-lien-tuc-o-benh-nhan-suy-tim-quan-sat-tu-thu-nghiem-alleviate-hf/Medxy AIvi2026-06-03T09:39:09-07:00Gánh nặng loạn nhịp và đáp ứng lâm sàng khi theo dõi liên tục ở bệnh nhân suy tim: Quan sát từ thử nghiệm ALLEVIATE-HF https://news.medxy.ai/arrhythmia-burden-and-clinical-responses-under-continuous-monitoring-in-heart-failure-observations-from-the-alleviate-hf-trial/Medxy AIen2026-06-03T09:38:17-07:00Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial https://news.medxy.ai/zh/%e5%87%8f%e9%87%8d%e5%b9%b6%e9%9d%9e%e5%94%af%e4%b8%80%e5%85%b3%e9%94%ae%ef%bc%9a%e5%86%85%e8%84%8f%e8%84%82%e8%82%aa%e5%87%8f%e5%b0%91%e6%88%96%e6%98%af%e9%95%bf%e6%9c%9f%e5%bf%83%e4%bb%a3%e8%b0%a2/Medxy AIzh2026-06-03T09:35:45-07:00减重并非唯一关键：内脏脂肪减少或是长期心代谢健康更稳固的靶点 https://news.medxy.ai/ja/%e4%bd%93%e9%87%8d%e6%b8%9b%e5%b0%91%e3%81%a0%e3%81%91%e3%81%a7%e3%81%af%e4%b8%8d%e5%8d%81%e5%88%86%ef%bc%9f-%e9%95%b7%e6%9c%9f%e7%9a%84%e3%81%aa%e5%bf%83%e4%bb%a3%e8%ac%9d%e3%81%ae%e5%81%a5%e5%ba%b7/Medxy AIja2026-06-03T09:35:13-07:00体重減少だけでは不十分？ 長期的な心代謝の健康には内臓脂肪の減少がより重要かもしれない https://news.medxy.ai/vi/giam-mo-tang-chu-khong-chi-giam-can-muc-tieu-ben-vung-hon-cho-suc-khoe-tim-mach-chuyen-hoa-lau-dai/Medxy AIvi2026-06-03T09:34:37-07:00Giảm mỡ tạng, chứ không chỉ giảm cân: Mục tiêu bền vững hơn cho sức khỏe tim mạch-chuyển hóa lâu dài https://news.medxy.ai/visceral-fat-loss-not-weight-loss-alone-may-be-the-more-durable-target-for-long-term-cardiometabolic-health/Medxy AIen2026-06-03T09:32:54-07:00Visceral Fat Loss, Not Weight Loss Alone, May Be the More Durable Target for Long-Term Cardiometabolic Health https://news.medxy.ai/ja/%e9%80%b2%e8%a1%8c%e4%b9%b3%e7%99%8c%e3%81%ae%e5%88%9d%e5%9b%9e%e6%b2%bb%e7%99%82%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8bfovinaciclib%ef%bc%9a%e3%83%a9%e3%83%b3%e3%83%80%e3%83%a0%e5%8c%96%e8%87%a8/Medxy AIja2026-06-03T09:29:03-07:00進行乳癌の初回治療におけるfovinaciclib：ランダム化臨床試験 https://news.medxy.ai/vi/fovinaciclib-trong-dieu-tri-hang-dau-dong-dau-tay-ung-thu-vu-tien-trien-ket-qua-tu-mot-thu-nghiem-lam-sang-ngau-nhien/Medxy AIvi2026-06-03T09:28:37-07:00Fovinaciclib trong điều trị hàng đầu dòng đầu tay ung thư vú tiến triển: Kết quả từ một thử nghiệm lâm sàng ngẫu nhiên https://news.medxy.ai/fovinaciclib-for-first-line-therapy-of-advanced-breast-cancer-a-randomized-clinical-trial/Medxy AIen2026-06-03T09:27:48-07:00Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial https://news.medxy.ai/ja/%e3%81%86%e3%81%a4%e7%97%85%e3%81%ab%e5%af%be%e3%81%99%e3%82%8bmst%e3%81%a8%e5%8f%b3%e7%89%87%e5%81%b4%e8%b6%85%e7%9f%ad%e3%83%91%e3%83%ab%e3%82%b9ect%e3%81%ae%e6%9c%89%e5%8a%b9%e6%80%a7%e3%83%bb/Medxy AIja2026-06-03T00:21:44-07:00うつ病に対するMSTと右片側超短パルスECTの有効性・安全性を検証した確認試験 https://news.medxy.ai/vi/thu-nghiem-xac-nhan-ve-hieu-qua-va-do-an-toan-cua-lieu-phap-co-giat-tu-truong-so-voi-ect-mot-ben-phai-xung-sieu-ngan-trong-dieu-tri-tram-cam/Medxy AIvi2026-06-03T00:21:20-07:00Thử nghiệm xác nhận về hiệu quả và độ an toàn của liệu pháp co giật từ trường so với ECT một bên phải, xung siêu ngắn trong điều trị trầm cảm https://news.medxy.ai/confirmatory-efficacy-and-safety-trial-of-magnetic-seizure-therapy-versus-right-unilateral-ultra-brief-electroconvulsive-therapy-in-depression/Medxy AIen2026-06-03T00:20:35-07:00Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy Versus Right Unilateral Ultra-Brief Electroconvulsive Therapy in Depression https://news.medxy.ai/ja/%e3%81%86%e3%81%a4%e7%97%85%e6%b2%bb%e7%99%82%e3%81%ae%e6%96%b0%e3%81%9f%e3%81%aa%e6%a8%99%e7%9a%84%ef%bc%9a%e3%82%a4%e3%83%b3%e3%82%bf%e3%83%bc%e3%83%ad%e3%82%a4%e3%82%ad%e3%83%b36%e9%81%ae%e6%96%ad/Medxy AIja2026-06-03T00:02:53-07:00うつ病治療の新たな標的：インターロイキン6遮断を検証した概念実証無作為化臨床試験 https://news.medxy.ai/vi/tocilizumab-nham-vao-il-6-trien-vong-moi-trong-dieu-tri-tram-cam-lien-quan-viem/Medxy AIvi2026-06-03T00:02:29-07:00Tocilizumab nhắm vào IL-6: triển vọng mới trong điều trị trầm cảm liên quan viêm https://news.medxy.ai/interleukin-6-as-a-treatment-target-for-depression-a-proof-of-concept-randomized-clinical-trial/Medxy AIen2026-06-03T00:01:40-07:00Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial https://news.medxy.ai/zh/%e9%87%8d%e6%96%b0%e5%ae%a1%e8%a7%86%e5%bf%83%e8%84%8f%e5%a4%96%e7%a7%91%e6%9c%af%e5%90%8e%e6%88%bf%e9%a2%a4%e7%9a%84%e9%95%81%e9%a2%84%e9%98%b2%ef%bc%9a%e4%b8%b4%e5%ba%8a%e8%af%81%e6%8d%ae%e7%9a%84/Medxy AIzh2026-06-02T23:59:57-07:00重新审视心脏外科术后房颤的镁预防：临床证据的综合分析 https://news.medxy.ai/ja/%e5%bf%83%e8%87%93%e6%89%8b%e8%a1%93%e5%be%8c%e3%81%ae%e8%a1%93%e5%be%8c%e5%bf%83%e6%88%bf%e7%b4%b0%e5%8b%95%e4%ba%88%e9%98%b2%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e3%83%9e%e3%82%b0%e3%83%8d%e3%82%b7/Medxy AIja2026-06-02T23:59:40-07:00心臓手術後の術後心房細動予防におけるマグネシウム投与を再考する：臨床エビデンスの統合 https://news.medxy.ai/vi/xem-xet-lai-du-phong-bang-magie-doi-voi-rung-nhi-sau-phau-thuat-trong-phau-thuat-tim-tong-hop-bang-chung-lam-sang/Medxy AIvi2026-06-02T23:59:19-07:00Xem xét lại dự phòng bằng magiê đối với rung nhĩ sau phẫu thuật trong phẫu thuật tim: Tổng hợp bằng chứng lâm sàng https://news.medxy.ai/rethinking-magnesium-prophylaxis-for-postoperative-atrial-fibrillation-in-cardiac-surgery-a-synthesis-of-clinical-evidence/Medxy AIen2026-06-02T23:58:00-07:00Rethinking Magnesium Prophylaxis for Postoperative Atrial Fibrillation in Cardiac Surgery: A Synthesis of Clinical Evidence https://news.medxy.ai/extracorporeal-cpr-may-improve-survival-after-pediatric-out-of-hospital-cardiac-arrest-but-evidence-remains-early/Medxy AIen2026-06-02T22:07:15-07:00Extracorporeal CPR May Improve Survival After Pediatric Out-of-Hospital Cardiac Arrest, but Evidence Remains Early https://news.medxy.ai/vi/ecpr-ngoai-co-the-trong-ngung-tim-ngoai-benh-vien-o-tre-em/Medxy AIvi2026-06-02T22:06:01-07:00ECPR ngoài cơ thể trong ngừng tim ngoài bệnh viện ở trẻ em https://news.medxy.ai/extracorporeal-cardiopulmonary-resuscitation-for-pediatric-out-of-hospital-cardiac-arrest/Medxy AIen2026-06-02T22:05:20-07:00Extracorporeal Cardiopulmonary Resuscitation for Pediatric Out-of-Hospital Cardiac Arrest https://news.medxy.ai/ja/%e8%82%a1%e9%96%a2%e7%af%80%e3%83%bb%e8%86%9d%e9%96%a2%e7%af%80%e7%bd%ae%e6%8f%9b%e8%a1%93%e5%be%8c%e3%81%ae%e6%8a%97%e5%87%9d%e5%9b%ba%e7%99%82%e6%b3%95%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e6%82%a3/Medxy AIja2026-06-02T22:03:22-07:00股関節・膝関節置換術後の抗凝固療法における患者選好の類型 https://news.medxy.ai/vi/ba-kieu-uu-tien-cua-benh-nhan-khi-dung-thuoc-chong-dong-sau-thay-khop-hang-hoac-khop-goi/Medxy AIvi2026-06-02T22:02:58-07:00Ba kiểu ưu tiên của bệnh nhân khi dùng thuốc chống đông sau thay khớp háng hoặc khớp gối https://news.medxy.ai/patient-preference-phenotypes-for-post-operative-anticoagulation-after-hip-or-knee-replacement/Medxy AIen2026-06-02T22:02:17-07:00Patient Preference Phenotypes for Post-operative Anticoagulation After Hip or Knee Replacement https://news.medxy.ai/patient-preference-phenotypes-for-post-operative-anticoagulation-after-hip-or-knee-replacement-a-cross-sectional-survey-study/Medxy AIen2026-06-02T20:13:26-07:00Patient Preference Phenotypes for Post-operative Anticoagulation After Hip or Knee Replacement: A Cross-sectional Survey Study https://news.medxy.ai/ja/%e5%8c%bb%e7%99%82%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e3%83%97%e3%83%a9%e3%82%a4%e3%83%99%e3%83%bc%e3%83%88%e3%83%bb%e3%82%a8%e3%82%af%e3%82%a4%e3%83%86%e3%82%a3%e3%81%a8%e4%bc%81%e6%a5%ad%e5%8c%96/Medxy AIja2026-06-02T19:50:05-07:00医療におけるプライベート・エクイティと企業化の規制枠組み：ACPポジションペーパー https://news.medxy.ai/vi/khung-phap-ly-doi-voi-private-equity-va-doanh-nghiep-hoa-trong-cham-soc-suc-khoe-quan-diem-cua-acp/Medxy AIvi2026-06-02T19:49:40-07:00Khung pháp lý đối với private equity và doanh nghiệp hóa trong chăm sóc sức khỏe: Quan điểm của ACP https://news.medxy.ai/regulatory-framework-for-private-equity-and-corporatization-in-health-care-an-acp-position-paper/Medxy AIen2026-06-02T19:48:51-07:00Regulatory Framework for Private Equity and Corporatization in Health Care: An ACP Position Paper https://news.medxy.ai/ja/%e5%90%8c%e7%a8%ae%e9%80%a0%e8%a1%80%e5%b9%b9%e7%b4%b0%e8%83%9e%e7%a7%bb%e6%a4%8d%e5%be%8c%e3%81%ae%e6%97%a9%e6%9c%9f%e9%ab%98%e8%a7%a3%e5%83%8f%e5%ba%a6%e5%85%8d%e7%96%ab%e3%83%97%e3%83%ad%e3%83%95/Medxy AIja2026-06-02T17:02:44-07:00同種造血幹細胞移植後の早期高解像度免疫プロファイルは生存と再発を左右する https://news.medxy.ai/vi/ho-so-mien-dich-do-phan-giai-cao-giai-doan-som-lien-quan-den-song-con-va-tai-phat-sau-ghep-te-bao-goc-di-gen/Medxy AIvi2026-06-02T17:02:22-07:00Hồ sơ miễn dịch độ phân giải cao giai đoạn sớm liên quan đến sống còn và tái phát sau ghép tế bào gốc dị gen https://news.medxy.ai/early-high-resolution-immune-profiles-are-linked-to-survival-and-relapse-after-allogeneic-stem-cell-transplantation/Medxy AIen2026-06-02T17:01:38-07:00Early High-Resolution Immune Profiles Are Linked to Survival and Relapse After Allogeneic Stem Cell Transplantation https://news.medxy.ai/zh/%e6%af%8f%e5%91%a8%e4%b8%a4%e6%ac%a1%e5%85%a8%e5%8f%a3%e6%9c%8d-ixazomib%e3%80%81pomalidomide-%e8%81%94%e5%90%88-dexamethasone-%e5%9c%a8%e5%a4%8d%e5%8f%91-%e9%9a%be%e6%b2%bb%e6%80%a7%e5%a4%9a%e5%8f%91/Medxy AIzh2026-06-02T12:58:02-07:00每周两次全口服 ixazomib、pomalidomide 联合 dexamethasone 在复发/难治性多发性骨髓瘤中显示持久疗效 https://news.medxy.ai/ja/%e5%86%8d%e7%99%ba%e3%83%bb%e9%9b%a3%e6%b2%bb%e6%80%a7%e5%a4%9a%e7%99%ba%e6%80%a7%e9%aa%a8%e9%ab%84%e8%85%ab%e3%81%ab%e3%81%8a%e3%81%84%e3%81%a6%e3%80%81%e9%80%b12%e5%9b%9e%e3%81%ae%e5%ae%8c%e5%85%a8/Medxy AIja2026-06-02T12:57:07-07:00再発・難治性多発性骨髄腫において、週2回の完全経口イキサゾミブ＋ポマリドミド＋デキサメタゾンが持続的な有効性を示す https://news.medxy.ai/vi/ixazomib-pomalidomide-va-dexamethasone-duong-uong-hai-lan-moi-tuan-cho-thay-hieu-qua-ben-vung-o-da-u-tuy-tai-phat-khang-tri/Medxy AIvi2026-06-02T12:56:31-07:00Ixazomib, Pomalidomide và Dexamethasone đường uống hai lần mỗi tuần cho thấy hiệu quả bền vững ở đa u tủy tái phát/kháng trị https://news.medxy.ai/twice-weekly-all-oral-ixazomib-pomalidomide-and-dexamethasone-shows-durable-activity-in-relapsed-refractory-multiple-myeloma/Medxy AIen2026-06-02T12:54:49-07:00Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma https://news.medxy.ai/ja/b%e7%b4%b0%e8%83%9e%e6%80%a5%e6%80%a7%e3%83%aa%e3%83%b3%e3%83%91%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8bcd19-cd22%e4%ba%8c%e9%87%8d%e6%a8%99%e7%9a%84car-t%e7%b4%b0/Medxy AIja2026-06-02T12:01:11-07:00B細胞急性リンパ性白血病におけるCD19/CD22二重標的CAR T細胞療法後再発の細胞・分子機序 https://news.medxy.ai/vi/hieu-co-che-tai-phat-sau-lieu-phap-car-t-nham-dich-kep-cd19-cd22-trong-b-all/Medxy AIvi2026-06-02T12:00:53-07:00Hiểu cơ chế tái phát sau liệu pháp CAR T nhắm đích kép CD19/CD22 trong B-ALL https://news.medxy.ai/cellular-and-molecular-mechanisms-of-relapse-after-cd19-cd22-dual-target-car-t-cell-therapy-in-b-cell-acute-lymphoblastic-leukemia/Medxy AIen2026-06-02T12:00:15-07:00Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia https://news.medxy.ai/anti-cd117-conditioning-with-briquilimab-shows-feasibility-and-stem-cell-depletion-in-older-adults-undergoing-allogeneic-transplant-for-high-risk-aml-and-mds/Medxy AIen2026-06-02T11:44:17-07:00Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS https://news.medxy.ai/zh/ct%e5%b0%8f%e5%8a%a8%e8%84%89%e5%87%8f%e5%b0%91%e6%af%94%e8%82%ba%e5%ae%9e%e8%b4%a8%e6%8d%9f%e4%bc%a4%e6%9b%b4%e8%83%bd%e6%8f%90%e7%a4%bacopd%e4%b8%8e%e7%ba%a4%e7%bb%b4%e5%8c%96%e6%80%a7ild%e4%b8%ad/Medxy AIzh2026-06-02T09:23:14-07:00CT小动脉减少比肺实质损伤更能提示COPD与纤维化性ILD中的重度肺动脉高压 https://news.medxy.ai/ja/copd%e3%81%a8%e7%b7%9a%e7%b6%ad%e5%8c%96%e6%80%a7ild%e3%81%ae%e9%87%8d%e7%97%87%e8%82%ba%e9%ab%98%e8%a1%80%e5%9c%a7%e7%97%87%e3%82%92%e6%98%a0%e3%81%99ct%e8%a1%80%e7%ae%a1%e6%8c%87%e6%a8%99%e2%80%95/Medxy AIja2026-06-02T09:22:42-07:00COPDと線維化性ILDの重症肺高血圧症を映すCT血管指標――実質障害より鋭敏な小動脈減少の評価 https://news.medxy.ai/vi/ct-cho-thay-mat-dong-mach-nho-lien-quan-chat-voi-tang-ap-dong-mach-phoi-nang-o-copd-va-ild-xo-hoa-hon-la-ton-thuong-nhu-mo/Medxy AIvi2026-06-02T09:22:04-07:00CT cho thấy mất động mạch nhỏ liên quan chặt với tăng áp động mạch phổi nặng ở COPD và ILD xơ hóa hơn là tổn thương nhu mô https://news.medxy.ai/ct-small-artery-loss-tracks-severe-pulmonary-hypertension-in-copd-and-fibrosing-ild-more-closely-than-parenchymal-damage/Medxy AIen2026-06-02T09:20:07-07:00CT Small-Artery Loss Tracks Severe Pulmonary Hypertension in COPD and Fibrosing ILD More Closely Than Parenchymal Damage https://news.medxy.ai/ja/%e9%9b%bb%e5%ad%90%e9%bc%bb%e3%81%af%e7%b7%9a%e7%b6%ad%e6%80%a7%e9%96%93%e8%b3%aa%e6%80%a7%e8%82%ba%e7%96%be%e6%82%a3%e3%82%92%e8%a6%8b%e5%88%86%e3%81%91%e3%82%89%e3%82%8c%e3%82%8b%e3%81%8b%e3%80%80/Medxy AIja2026-06-02T09:16:46-07:00電子鼻は線維性間質性肺疾患を見分けられるか　国際検証で示された診断支援の可能性 https://news.medxy.ai/vi/xac-thuc-quoc-te-cong-nghe-mui-dien-tu-trong-chan-doan-benh-phoi-ke-xo-hoa/Medxy AIvi2026-06-02T09:16:23-07:00Xác thực quốc tế công nghệ mũi điện tử trong chẩn đoán bệnh phổi kẽ xơ hóa https://news.medxy.ai/international-validation-of-electronic-nose-technology-as-a-diagnostic-tool-for-fibrotic-interstitial-lung-diseases-2/Medxy AIen2026-06-02T09:15:39-07:00International Validation of Electronic Nose Technology as a Diagnostic Tool for Fibrotic Interstitial Lung Diseases https://news.medxy.ai/international-validation-of-electronic-nose-technology-as-a-diagnostic-tool-for-fibrotic-interstitial-lung-diseases/Medxy AIen2026-06-02T09:09:34-07:00International Validation of Electronic Nose Technology as a Diagnostic Tool for Fibrotic Interstitial Lung Diseases https://news.medxy.ai/ja/%e5%be%ae%e5%b0%8f%e8%a1%80%e7%ae%a1%e6%b6%88%e5%a4%b1%e3%81%ae%e6%9c%89%e7%84%a1%e3%81%a7%e3%81%bf%e3%82%8b%e5%89%8d%e8%a6%96%e9%87%8e%e7%b7%91%e5%86%85%e9%9a%9c%e3%81%ae%e9%80%b2%e8%a1%8c%e4%ba%88/Medxy AIja2026-06-02T09:05:11-07:00微小血管消失の有無でみる前視野緑内障の進行予測 https://news.medxy.ai/vi/glocom-tien-thi-truong-mat-vi-mach-nen-du-bao-tien-trien-nhanh-hon-va-nguy-co-ton-thuong-thi-truong-cao-hon/Medxy AIvi2026-06-02T09:04:50-07:00Glôcôm tiền thị trường: mất vi mạch nền dự báo tiến triển nhanh hơn và nguy cơ tổn thương thị trường cao hơn https://news.medxy.ai/progression-in-preperimetric-glaucoma-eyes-with-and-without-microvasculature-dropout-2/Medxy AIen2026-06-02T09:04:03-07:00Progression in Preperimetric Glaucoma Eyes With and Without Microvasculature Dropout https://news.medxy.ai/vi/tien-trien-o-mat-glocom-tien-thi-truong-co-va-khong-co-mat-vi-mach/Medxy AIvi2026-06-02T08:17:19-07:00Tiến triển ở mắt glôcôm tiền thị trường có và không có mất vi mạch https://news.medxy.ai/progression-in-preperimetric-glaucoma-eyes-with-and-without-microvasculature-dropout/Medxy AIen2026-06-02T08:16:22-07:00Progression in Preperimetric Glaucoma Eyes With and Without Microvasculature Dropout https://news.medxy.ai/ja/%e7%97%85%e7%90%86%e6%80%a7%e8%bf%91%e8%a6%96%e3%81%ae%e7%9c%bc%e7%90%83%e5%bd%a2%e7%8a%b6%e3%81%8c%e7%a4%ba%e3%81%99%e9%95%b7%e6%9c%9f%e4%ba%88%e5%be%8c/Medxy AIja2026-06-01T23:42:14-07:00病理性近視の眼球形状が示す長期予後 https://news.medxy.ai/vi/hinh-dang-nhan-cau-trong-can-thi-benh-ly-tien-luong-dai-han-cho-thay-dieu-gi/Medxy AIvi2026-06-01T23:41:50-07:00Hình dạng nhãn cầu trong cận thị bệnh lý: tiên lượng dài hạn cho thấy điều gì? https://news.medxy.ai/pathologic-myopia-globe-shape-and-long-term-prognosis/Medxy AIen2026-06-01T23:40:59-07:00Pathologic Myopia Globe Shape and Long-Term Prognosis https://news.medxy.ai/ja/%e6%89%81%e6%a1%83%e6%91%98%e5%87%ba%e8%a1%93%e5%be%8c%e5%87%ba%e8%a1%80%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e3%83%8d%e3%83%96%e3%83%a9%e3%82%a4%e3%82%b6%e3%83%bc%e6%8a%95%e4%b8%8e%e3%83%88%e3%83%a9/Medxy AIja2026-06-01T23:19:38-07:00扁桃摘出術後出血におけるネブライザー投与トラネキサム酸：臨床ケアガイドライン導入の効果 https://news.medxy.ai/zh/%e6%89%81%e6%a1%83%e4%bd%93%e5%88%87%e9%99%a4%e6%9c%af%e5%90%8e%e5%87%ba%e8%a1%80%e4%b8%ad%e9%9b%be%e5%8c%96%e6%b0%a8%e7%94%b2%e7%8e%af%e9%85%b8%e7%9a%84%e4%b8%b4%e5%ba%8a%e6%8a%a4%e7%90%86%e6%8c%87/Medxy AIzh2026-06-01T23:19:11-07:00扁桃体切除术后出血中雾化氨甲环酸的临床护理指南实施 https://news.medxy.ai/clinical-care-guideline-implementation-of-nebulized-tranexamic-acid-in-post-tonsillectomy-hemorrhage-2/Medxy AIen2026-06-01T23:17:59-07:00Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage https://news.medxy.ai/a-post-tonsillectomy-hemorrhage-guideline-using-nebulized-tranexamic-acid-was-associated-with-fewer-returns-to-the-operating-room/Medxy AIen2026-06-01T23:14:40-07:00A Post-Tonsillectomy Hemorrhage Guideline Using Nebulized Tranexamic Acid Was Associated With Fewer Returns to the Operating Room https://news.medxy.ai/clinical-care-guideline-implementation-of-nebulized-tranexamic-acid-in-post-tonsillectomy-hemorrhage/Medxy AIen2026-06-01T22:58:25-07:00Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage https://news.medxy.ai/a-clinical-care-guideline-for-nebulized-tranexamic-acid-was-associated-with-fewer-operating-room-returns-after-post-tonsillectomy-hemorrhage/Medxy AIen2026-06-01T22:33:11-07:00A Clinical Care Guideline for Nebulized Tranexamic Acid Was Associated With Fewer Operating Room Returns After Post-Tonsillectomy Hemorrhage https://news.medxy.ai/a-standardized-emergency-department-guideline-for-nebulized-tranexamic-acid-was-linked-to-fewer-operating-room-returns-after-post-tonsillectomy-hemorrhage/Medxy AIen2026-06-01T22:30:40-07:00A Standardized Emergency Department Guideline for Nebulized Tranexamic Acid Was Linked to Fewer Operating Room Returns After Post-Tonsillectomy Hemorrhage https://news.medxy.ai/a-pain-predominant-dry-eye-phenotype-emerges-severe-symptoms-few-ocular-signs-and-strong-links-to-migraine-and-psychiatric-disease/Medxy AIen2026-06-01T22:29:32-07:00A Pain-Predominant Dry Eye Phenotype Emerges: Severe Symptoms, Few Ocular Signs, and Strong Links to Migraine and Psychiatric Disease https://news.medxy.ai/internet-based-cbt-for-tinnitus-shows-durable-benefit-up-to-6-years-but-long-term-interpretation-requires-caution/Medxy AIen2026-06-01T22:20:17-07:00Internet-Based CBT for Tinnitus Shows Durable Benefit Up to 6 Years, but Long-Term Interpretation Requires Caution https://news.medxy.ai/internet-based-cbt-for-tinnitus-shows-durable-benefit-up-to-6-years-with-sustained-reduction-in-distress-but-more-modest-auditory-gains/Medxy AIen2026-06-01T22:15:13-07:00Internet-Based CBT for Tinnitus Shows Durable Benefit Up to 6 Years, With Sustained Reduction in Distress but More Modest Auditory Gains https://news.medxy.ai/a-post-tonsillectomy-hemorrhage-guideline-with-nebulized-tranexamic-acid-was-linked-to-fewer-returns-to-the-operating-room/Medxy AIen2026-06-01T22:11:42-07:00A Post-Tonsillectomy Hemorrhage Guideline With Nebulized Tranexamic Acid Was Linked to Fewer Returns to the Operating Room https://news.medxy.ai/relaxing-diaphragmatic-incisions-may-improve-symptom-outcomes-in-difficult-hiatal-hernia-repair-but-morphologic-durability-remains-unproven/Medxy AIen2026-06-01T21:50:05-07:00Relaxing Diaphragmatic Incisions May Improve Symptom Outcomes in Difficult Hiatal Hernia Repair, but Morphologic Durability Remains Unproven https://news.medxy.ai/role-of-relaxing-lateral-incisions-as-an-add-on-to-difficult-hiatal-repair-in-redo-and-giant-hernia-cases/Medxy AIen2026-06-01T21:48:16-07:00Role of Relaxing Lateral Incisions as an Add-On to Difficult Hiatal Repair in Redo and Giant Hernia Cases https://news.medxy.ai/onlay-mesh-was-linked-to-lower-reoperation-and-bowel-obstruction-risk-than-retromuscular-or-ipom-repair-in-primary-ventral-hernia-surgery/Medxy AIen2026-06-01T21:28:48-07:00Onlay Mesh Was Linked to Lower Reoperation and Bowel Obstruction Risk Than Retromuscular or IPOM Repair in Primary Ventral Hernia Surgery https://news.medxy.ai/pancreatic-cancer-risk-during-ipmn-surveillance-is-about-10-fold-higher-than-in-the-general-population/Medxy AIen2026-06-01T19:35:13-07:00Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population https://news.medxy.ai/pancreatic-cancer-risk-during-ipmn-surveillance-a-seer-based-comparison/Medxy AIen2026-06-01T19:31:06-07:00Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison https://news.medxy.ai/more-than-half-of-patients-with-atypical-endometrial-hyperplasia-had-occult-cancer-at-hysterectomy-in-a-minority-enriched-urban-cohort/Medxy AIen2026-06-01T19:28:56-07:00More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort https://news.medxy.ai/predictors-of-concurrent-endometrial-carcinoma-in-minority-populations-with-atypical-hyperplasia-a-synthesis-of-clinical-molecular-and-social-evidence/Medxy AIen2026-06-01T17:47:43-07:00Predictors of Concurrent Endometrial Carcinoma in Minority Populations with Atypical Hyperplasia: A Synthesis of Clinical, Molecular, and Social Evidence https://news.medxy.ai/minimal-access-vs-open-hysterectomy-in-endometrial-cancer-a-critical-synthesis-of-surgical-and-survival-outcomes/Medxy AIen2026-06-01T13:00:51-07:00Minimal Access vs. Open Hysterectomy in Endometrial Cancer: A Critical Synthesis of Surgical and Survival Outcomes https://news.medxy.ai/maternal-fetal-alloimmunity-and-gestational-outcomes-assessing-anti-hla-antibodies-as-a-risk-factor-for-fetal-growth-restriction/Medxy AIen2026-06-01T12:20:38-07:00Maternal-Fetal Alloimmunity and Gestational Outcomes: Assessing Anti-HLA Antibodies as a Risk Factor for Fetal Growth Restriction https://news.medxy.ai/postmarketing-data-link-fezolinetant-primarily-to-early-transaminase-elevations-rather-than-overt-liver-injury/Medxy AIen2026-06-01T12:03:35-07:00Postmarketing Data Link Fezolinetant Primarily to Early Transaminase Elevations Rather Than Overt Liver Injury https://news.medxy.ai/targeted-galectin-3-inhibition-for-portal-hypertension-insights-from-the-navigate-trial-and-belapectins-role-in-mash-cirrhosis/Medxy AIen2026-06-01T11:38:15-07:00Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis https://news.medxy.ai/galectin-3-inhibition-in-mash-cirrhosis-synthesizing-evidence-from-the-navigate-trial-and-emerging-therapeutics/Medxy AIen2026-06-01T11:02:58-07:00Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics https://news.medxy.ai/belapectin-for-the-prevention-of-esophageal-varices-in-mash-cirrhosis-insights-from-the-navigate-phase-2b-trial/Medxy AIen2026-06-01T10:59:12-07:00Belapectin for the Prevention of Esophageal Varices in MASH Cirrhosis: Insights from the NAVIGATE Phase 2b Trial https://news.medxy.ai/exercise-may-be-a-disease-modifying-strategy-in-chronic-pancreatitis/Medxy AIen2026-06-01T10:55:49-07:00Exercise May Be a Disease-Modifying Strategy in Chronic Pancreatitis https://news.medxy.ai/therapeutic-mobilization-how-physical-activity-reprograms-the-pancreatic-immune-microenvironment-to-combat-chronic-pancreatitis/Medxy AIen2026-06-01T10:23:30-07:00Therapeutic Mobilization: How Physical Activity Reprograms the Pancreatic Immune Microenvironment to Combat Chronic Pancreatitis https://news.medxy.ai/fermentable-fiber-subtypes-in-crohns-disease-from-primary-prevention-to-mechanistic-regulation-of-the-gut-immune-axis/Medxy AIen2026-06-01T10:18:20-07:00Fermentable Fiber Subtypes in Crohn’s Disease: From Primary Prevention to Mechanistic Regulation of the Gut-Immune Axis